Antibodies that bind to CTLA-4 and their applications

TW202633681APending Publication Date: 2026-08-16HARBOUR BIOMED (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114137526
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-04-14
Filing Date
2022-04-20
Publication Date
2026-08-16

Smart Images

  • Figure TWG2TA001072651_001
    Figure TWG2TA001072651_001
  • Figure TWG2TA001072651_002
    Figure TWG2TA001072651_002
  • Figure TWG2TA001072651_003
    Figure TWG2TA001072651_003
Patent Text Reader

Abstract

This disclosure relates to methods for eliminating regulatory T cells (Tregs) and / or increasing the CD8+ T cell / Treg ratio in subjects, methods for treating refractory cancers in subjects, combination therapies for treating cancer, methods for reducing the side effects of CTLA4 antibody therapy for cancer, methods for achieving long-term or necessary administration to cancer patients, methods for administering anti-CTLA-4 single-chain antibodies, unit dose compositions, use of anti-CTLA-4 single-chain antibodies in the preparation of pharmaceuticals, methods for determining the dosage of antitumor drugs, and methods for determining the form of administration of antitumor drugs.
Need to check novelty before this filing date? Find Prior Art